ThromboGenics Activates 50th Retina Center for its US Observational Patient Trial with JETREA® (ORBIT)

Quick activation rate underwrites strong commitment by the US Retina Community to help provide further insight and support in the use of JETREA® for the treatment of symptomatic vitreomacular adhesion

Leuven, Belgium – 29 April, 2014 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that the 50th retina center has been activated to evaluate patients in the US ORBIT Phase IV study with JETREA®. ORBIT (Ocriplasmin Research to Better Inform Treatment) is an observational study designed to generate further data on the real-world use of JETREA® in the US. Patient enrollment is open and underway at all activated sites.

ORBIT will recruit 1,500 patients with symptomatic vitreomacular adhesion (VMA) across 120 retina centers in the US. The prospective, observational study will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic VMA/VMT by assessing both anatomical and functional outcomes.

The study will look at a number of parameters including resolution of VMA, Full Thickness Macular Hole (FTMH) closure, changes in visual acuity (VA) and occurrence and time to vitrectomy. It will also monitor adverse drug reactions (ADRs) and changes from baseline in ocular signs and symptoms across time. These data will further characterize the efficacy and safety profile of the product and provide data complementary to those from the phase III clinical program and its first 15 months on the market. .

Patients will be followed for up to 12 months following treatment with JETREA®. The ORBIT study is due to complete in mid-2016. Data will be presented on a regular basis. First data may be expected as early as by the end of 2014.

"I congratulate ThromboGenics on gathering real world data on the use of JETREA® *for the treatment of symptomatic vitreomacular adhesion. By analyzing this large cohort we will be able to better determine which patients most benefit from this treatment and to also see the results of surgical intervention if needed. With this observational study, incidence of adverse events and true success rate can be further characterized,"* said David Boyer, MD- Retina-Vitreous Associates Medical Group, Beverly Hills, CA.

Dr Patrik De Haes, CEO of ThromboGenics, comments*: "We are pleased to see this high level of interest from the US retina community to take part in the ORBIT study. With 50 centers already in a position to recruit patients, we are optimistic that we can complete this study by mid-2016, with first data potentially available by end of 2014. ThromboGenics´decision to undertake the ORBIT study underwrites our commitment to help the community gain further knowledge about the real world use of JETREA® and in particular to understand which patients gain the greatest benefit from the first pharmacological option for the treatment of symptomatic VMA/VMT. "*

Ends

For further information please contact:

ThromboGenics	**Citigate Dewe Rogerson**
Wouter Piepers, Global Head of Corporate Communications +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@thrombogenics.com	David Dible/ Sita Shah Tel: +44 20 7638 9571 sita.shah@citigatedr.co.uk

About JETREA® (ocriplasmin)

JETREA® (ocriplasmin) is a truncated form of human plasmin. JETREA® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.

In the US and Canada, JETREA® is indicated for the treatment of symptomatic vitreomacular adhesion (VMA). In Europe, JETREA® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤ 400 microns.

JETREA® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the US and Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.

JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo ($p<0.01$). The Phase III program also showed that JETREA was generally well tolerated with most adverse events being transient and mild in severity.

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.

In Europe, JETREA® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics and Alcon intend to share the costs equally of developing JETREA® for a number of new vitreoretinal indications.

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of oncology indications.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.